在怀孕期间甲福明是否安全:关注后代的结果
1Department of Internal Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA.
Expert opinion on drug safety
|November 1, 2024
概括
甲胺对患有2型糖尿病 (T2DM),妊娠期糖尿病 (GDM) 和多囊性卵巢综合征 (PCOS) 的母亲有益,但长期对后代的影响需要进一步研究.
科学领域:
- 生殖内分泌和产科. 生殖内分泌和产科.
- 药理学和母胎医学. 母胎医学.
背景情况:
- 甲胺广泛用于2型糖尿病 (T2DM) 和非标签用于妊娠糖尿病 (GDM),多囊性卵巢综合征 (PCOS) 和卵巢过度刺激的预防.
- 它作为胰岛素敏感剂,在这些条件下解决胰岛素耐药性.
- 在2022年,甲福明成为欧盟唯一的口服抗糖尿病妊娠药,尽管它穿过胎盘,但母亲的好处已被记录在案.
研究的目的:
- 审查关于在怀孕中使用甲福明的随机对照试验,这些试验涉及PCOS,GDM,T2DM和肥胖症复杂的怀孕.
- 检查这些试验中的后代随访数据.
主要方法:
- 主要随机对照试验 (RCT) 的系统审查.
- 对母亲和新生儿结局的分析.
- 对长期后代随访数据的评估.
主要成果:
- 孕产妇的好处包括减少胰岛素需求,体重增加,低血糖和孕前.
- 新生儿的好处可能包括降低低血糖和不增加先天性异常风险.
- 长期后代数据是有限的,有关怀孕年龄小 (SGA) 和改变的人类测量的担忧.
结论:
- 甲胺在各种与怀孕相关的疾病中为母亲提供福利.
- 虽然对于新生儿来说通常是安全的,但长期后代的健康结果仍然是需要继续调查的领域.
- 需要进一步的研究才能充分了解子宫内甲福明暴露的长期影响.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175
Pathophysiology of Diabetes
872
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
872
Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152


